Spain’s credit rating upgraded to ’A+’ by S&P on strong growth
Monogram Technologies Inc. (NASDAQ:MGRM), whose stock has surged over 150% in the past six months and currently trades near its 52-week high of $6.02, announced Thursday that Zimmer Biomet Holdings, Inc., in consultation with Monogram, has voluntarily withdrawn and resubmitted its pre-merger notification to the Federal Trade Commission (FTC) regarding their proposed merger. According to InvestingPro data, the company maintains a healthy balance sheet with a current ratio of 2.16. The resubmission, made under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act), initiates a new 30-day waiting period for regulatory review, set to expire on October 6, 2025, unless terminated earlier or extended.
According to a statement based on a recent SEC filing, this procedure is intended to provide the FTC with additional time to review the transaction. The agreement and plan of merger, originally signed on July 11, 2025, and amended on August 27, 2025, outlines that Monogram Technologies, currently valued at $244.2 million, would become a wholly owned subsidiary of Zimmer Biomet upon completion of the merger. Analysts maintain a Strong Buy consensus on MGRM with price targets ranging from $6.00 to $10.80.
Both companies stated that withdrawing and refiling pre-merger notifications is a standard practice to allow more time for antitrust review of certain transactions. Monogram Technologies and Zimmer Biomet said they are continuing to cooperate with FTC staff as the review proceeds. Get deeper insights into MGRM’s financial health and 10+ additional ProTips with InvestingPro’s comprehensive research report.
The companies reiterated their expectation to close the merger in the second half of 2025, subject to regulatory approvals, shareholder adoption of the merger agreement, and customary closing conditions.
This information is based on a statement released in a Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Monogram Technologies is at the center of significant corporate developments as it moves forward with a proposed acquisition by Zimmer Biomet Holdings. The company has begun notifying shareholders about a special meeting to vote on this acquisition, initially announced in July 2025. Additionally, Monogram Technologies has amended the merger agreement with Zimmer Biomet, adjusting the definition of "Permitted Transfer" in response to comments from the Securities and Exchange Commission. To address shareholder inquiries, Monogram has also released a set of frequently asked questions regarding the acquisition. In a separate development, Monogram terminated its Exclusive License Agreement with the Icahn School of Medicine at Mount Sinai. As part of the settlement, Monogram will pay $4 million, comprising cash and preferred stock. This acquisition deal, valued at approximately $177 million, includes a cash payment of $4.04 per share for all outstanding Monogram shares. Furthermore, Monogram shareholders stand to gain from a contingent value right that could yield additional payments if certain milestones are met.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.